"Capan-1人胰腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

【細(xì)胞培養(yǎng)經(jīng)驗分享】啟蒙老師的重要性：一般進(jìn)實驗室都有師兄師姐帶著做，他們就是你做細(xì)胞的啟蒙老師。他們的操作手法、細(xì)節(jié)、理論講解就成了你操作的準(zhǔn)則，如營養(yǎng)液、細(xì)胞瓶的擺放位置、滅菌處理程序、開蓋手法、細(xì)胞吹打手法等等。要學(xué)會他們的正確操作，在第一次的時候就要重視。像養(yǎng)孩子一樣養(yǎng)細(xì)胞，細(xì)胞有時真的很脆弱，最好每天都去看看它，以防止出現(xiàn)培養(yǎng)箱缺水、缺二氧化碳、停電、溫度不夠等異?，F(xiàn)象，也好及時解決這些意外，避免重復(fù)實驗帶來的更大痛苦。好細(xì)胞要及時保種：細(xì)胞要分批傳代，這樣即使有一批出了問題，還有一批備用的。像后者一般人可能不容易做到。但這是我血的教訓(xùn)，有一次細(xì)胞污染了，全軍覆沒。當(dāng)時可后悔沒有保種。細(xì)胞跟人一樣，不同的細(xì)胞，培養(yǎng)特性是不一樣的。培養(yǎng)過程中要細(xì)細(xì)體會，不同細(xì)胞系使用不同的培養(yǎng)基和血清。

換液周期：每周2-3次

BNCL-2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CAKI 2細(xì)胞、QGY-7701細(xì)胞、A72細(xì)胞

TSUpr1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：SNU761細(xì)胞、UCLA NPA871細(xì)胞、KG1細(xì)胞

HCET Cells;背景說明：角膜上皮細(xì)胞；Ad-SV４０轉(zhuǎn)化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI H295R細(xì)胞、FM88細(xì)胞、EA.hy 926細(xì)胞

Capan-1人胰腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：詳見相關(guān)文獻(xiàn)介紹

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

細(xì)胞培養(yǎng)應(yīng)用于分子生物學(xué)、細(xì)胞生物學(xué)、遺傳學(xué)、免疫學(xué)、腫瘤學(xué)及病毒學(xué)等領(lǐng)域，細(xì)胞培養(yǎng)是指將細(xì)胞從動物或植物體內(nèi)取出，然后在適宜的人工環(huán)境中生長的過程。細(xì)胞可以在培養(yǎng)前直接從組織中取出并通過酶或機(jī)械方法進(jìn)行解離，也可以來源于已建立的細(xì)胞系。傳代培養(yǎng)是指當(dāng)細(xì)胞生長至高密度時，將其分殖至新的培養(yǎng)瓶中，以維持其生長和增殖。貼壁細(xì)胞是指在培養(yǎng)基表面附著生長的細(xì)胞，懸浮細(xì)胞是指在培養(yǎng)基中懸浮生長的細(xì)胞，不依附于培養(yǎng)皿表面。半貼壁半懸浮細(xì)胞同時具備貼壁細(xì)胞和懸浮細(xì)胞的特點(diǎn)，通常在培養(yǎng)基中部分附著生長，部分懸浮于培養(yǎng)基上。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

Capan-1人胰腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來源：人源、鼠源等其它物種來源

Sci-1 Cells;背景說明：胚胎；自發(fā)永生;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Anip-973細(xì)胞、EC-9706細(xì)胞、ECC 10細(xì)胞

SK-N-FI Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４傳代，每周換液２次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Tb 1 Lu細(xì)胞、P3/X63/Ag8細(xì)胞、MCF 10A細(xì)胞

GM0637 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SUM149細(xì)胞、TOV112D細(xì)胞、Leukemic 1210細(xì)胞

SCaBER Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：QGY7703細(xì)胞、RGC6細(xì)胞、L 428細(xì)胞

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：上皮細(xì)胞樣

貼壁細(xì)胞消化傳代時通常采用兩種方法：一、加入胰酶等細(xì)胞脫落后，再加培養(yǎng)基中止胰酶作用，離心傳代；二、加入胰酶后，鏡下觀察待細(xì)胞始脫落時，棄胰酶，加培養(yǎng)分瓶。但前者太麻煩，而后者有可能對細(xì)胞施加胰酶選擇，因為總是貼壁不牢的細(xì)胞先脫落，對腫瘤細(xì)胞來說，這部分細(xì)胞有可能是惡性程度較GAO的細(xì)胞亞群。一種簡單的消化傳代方法。加入PBS洗去血清或加入胰酶先中和血清的作用(３０s)，棄之，再加入適量胰酶作用１０s-４０s(根據(jù)細(xì)胞消化的難易程度)，棄之，這樣依賴殘余的胰酶就可將細(xì)胞消化單細(xì)胞。對于較難消化的細(xì)胞，可以用２%利多卡因消化５-８分鐘，然后再棄去，加培養(yǎng)基吹打也可以，對細(xì)胞的影響不大。不用PBS也不用Hanks洗，只要把舊培養(yǎng)吸的干凈一點(diǎn)，直接加酶消化應(yīng)該不會有什么問題。棄培養(yǎng)后，用０.０４%的EDA沖洗一次，再用１/４v的０.０４%的EDA室溫孵育５min，棄取大部分EDA，加入與剩余EDA等量的胰酶(預(yù)熱)總體積１/１０v。消化到有細(xì)胞脫落。不過有人說EDA對細(xì)胞不HAO，有證據(jù)嗎？培養(yǎng)的BASMC：倒掉舊培養(yǎng)加入少量胰酶沖一下，倒掉再加入０.１２５-０.２５%胰酶約６-１０滴或１ml(２５ml bole)消化再加入適量新培養(yǎng)基中和，并分瓶這種方法簡單、省事；效果很HAO并且不損失細(xì)胞！

ATDC-5 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KMST-6細(xì)胞、OVCAR-3細(xì)胞、MBMEC細(xì)胞

SK-MEL3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：５傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：D283MED細(xì)胞、MDA-MB231細(xì)胞、PaTu 8988s細(xì)胞

HCS2/8 Cells;背景說明：軟骨肉瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SUSM-1細(xì)胞、CHP126細(xì)胞、H-2227細(xì)胞

RD 2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，３-４天換液１次。;生長特性：貼壁生長;形態(tài)特性：梭型和大的多核細(xì)胞;相關(guān)產(chǎn)品有：SACCLM細(xì)胞、PANC-10-05細(xì)胞、COLO-HSR細(xì)胞

H-2291 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：４傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：SuDHL 4細(xì)胞、BCaP-37細(xì)胞、HeLa/DDP細(xì)胞

L5178-R Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Karpas-299細(xì)胞、GM3190細(xì)胞、P3X63-Ag8.653細(xì)胞

HCoEpiC Cells;背景說明：結(jié)腸上皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：P36細(xì)胞、C8D1A細(xì)胞、HONE-1細(xì)胞

2BS Cells;背景說明：胚肺；成纖維細(xì)胞；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：alphaTC1 Clone 6細(xì)胞、NCI-H2030細(xì)胞、H69細(xì)胞

NK 10a Cells;背景說明：１９６７年，該細(xì)胞系KleinE和KleinG建系，源于一名１６歲患有Burkitt＇s淋巴瘤的黑人男性，beta-２-微球蛋白陰性，表達(dá)EBNA,VCA，sIg。該細(xì)胞攜帶EB病毒，是一個典型的B淋巴母細(xì)胞系，可用于白血病發(fā)病機(jī)制的研究。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：NCIH1734細(xì)胞、alpha TC1.6細(xì)胞、MPP-89細(xì)胞

MCF-7ADR Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Walker-Ca.256細(xì)胞、KASUMI1細(xì)胞、EJ 138細(xì)胞

H2009 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：MCF7細(xì)胞、OC-316細(xì)胞、HEK293-H細(xì)胞

V-79-4 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HBZY 1細(xì)胞、C3H/10T1/2 clone 8細(xì)胞、A204細(xì)胞

NCIH1650 Cells;背景說明：該細(xì)胞是從一名２７歲白人男性（１０年煙齡）支氣管肺泡癌患者的胸腔積液中分離得到的。;傳代方法：１：４-１：６傳代；２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：MUTZ1細(xì)胞、Anip973細(xì)胞、32Dc3細(xì)胞

NK10a Cells;背景說明：１９６７年，該細(xì)胞系KleinE和KleinG建系，源于一名１６歲患有Burkitt＇s淋巴瘤的黑人男性，beta-２-微球蛋白陰性，表達(dá)EBNA,VCA，sIg。該細(xì)胞攜帶EB病毒，是一個典型的B淋巴母細(xì)胞系，可用于白血病發(fā)病機(jī)制的研究。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：HuTu 80細(xì)胞、UMUC14細(xì)胞、SN12PM6細(xì)胞

Hs 822.T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SK-N-MC細(xì)胞、CV 1細(xì)胞、GCT0404細(xì)胞

EFM-192B Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH548細(xì)胞、CEK細(xì)胞、Hs 578T細(xì)胞

MOLT 4 Cells;背景說明：MOLT-４與MOLT-３來源于一名１９歲的男性急性淋巴細(xì)胞性白血病的復(fù)發(fā)患者，該患者前期接受過多種藥物聯(lián)合化療。MOLT-４細(xì)胞系為T淋巴細(xì)胞起源，p５３基因的第２４８位密碼子有一個G→A突變，不表達(dá)p５３，不表達(dá)免疫球蛋白或EB病毒；可產(chǎn)生高水平的末端脫氧核糖轉(zhuǎn)移酶；表達(dá)CD１(４９%),CD２(３５%),CD３A(２６%)B(３３%)C(３４%),CD４(５５%),CD５(７２%),CD６(２２%),CD７(７７%)。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣；圓形;相關(guān)產(chǎn)品有：NCI-H676B細(xì)胞、NBLAN5T細(xì)胞、TMK-1細(xì)胞

3Ao/cDDP Cells(提供STR鑒定圖譜)

Abcam HeLa ZRANB1 KO Cells(提供STR鑒定圖譜)

Akata delta2 EBER1(+) Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRJ374 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line Xk343 Cells(提供STR鑒定圖譜)

C822B Cells(提供STR鑒定圖譜)

DA00344 Cells(提供STR鑒定圖譜)

E246 Cells(提供STR鑒定圖譜)

GM04603 Cells(提供STR鑒定圖譜)

Panc-3_27 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：WiDr細(xì)胞、SUIT 2細(xì)胞、PC3M-2B4細(xì)胞

Capan-1人胰腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

KYSE70 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TF-1細(xì)胞、H-1838細(xì)胞、52PE細(xì)胞

MH-S Cells;背景說明：巨噬細(xì)胞；雄性；SV４０轉(zhuǎn)化；BALB/cJ;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Stanford University-Diffuse Histiocytic Lymphoma-1細(xì)胞、PC12(高分化)細(xì)胞、KE39細(xì)胞

TOV21G Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：４傳代，３-４天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：Ontario Cancer Institute-Acute Myeloid Leukemia-4細(xì)胞、PANC-1細(xì)胞、SNU398細(xì)胞

16HBE140 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-SNU-475細(xì)胞、LCLC-103H細(xì)胞、BTI-TN5B1-4細(xì)胞

AAV-293 Cells;背景說明：我們推薦使用AAV-２９３細(xì)胞株繁殖腺病毒相關(guān)重組病毒。 AAV-２９３源自普遍使用的 HEK２９３細(xì)胞株，但產(chǎn)生的病毒滴度更高。 HEK２９３細(xì)胞是剪切過的腺病毒５型DNA轉(zhuǎn)染的人胚腎細(xì)胞。 跟HEK２９３細(xì)胞一樣，AAV-２９３細(xì)胞反式表達(dá)腺病毒E１基因，當(dāng)共轉(zhuǎn)染三個AAV助質(zhì)粒(一個含ITR的質(zhì)粒，pAAV-RC, 和E１缺失助質(zhì)粒)時，可以產(chǎn)生有感染力的腺病毒-相關(guān)病毒顆粒。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：P19細(xì)胞、A1847細(xì)胞、HECV細(xì)胞

7F9 Cells(提供STR鑒定圖譜)

NCI H82 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：５傳代，每周換液２-３次;生長特性：懸浮生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：SP2/0 Ag-14細(xì)胞、SNU668細(xì)胞、Clone Y-1細(xì)胞

Jurkat Clone E6-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CNE2Z細(xì)胞、D-324MED細(xì)胞、RIN-m細(xì)胞

AML12 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MC-3T3-E1細(xì)胞、PIG3細(xì)胞、Panc-08.13細(xì)胞

HN4 Cells;背景說明：喉鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LA4細(xì)胞、MDA361細(xì)胞、H-1618細(xì)胞

HDQP1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Tissue Culture-1細(xì)胞、HuP-T4細(xì)胞、Ect1/E6E7細(xì)胞

Caov-4 Cells;背景說明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：IR983F細(xì)胞、Cor L51細(xì)胞、SW13細(xì)胞

RIN Cl-5F Cells;背景說明：胰島β細(xì)胞瘤；雄性；NEDH;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SNB19細(xì)胞、HCC9204細(xì)胞、GM15452細(xì)胞

HOC Cells;背景說明：肝；卵圓 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-2073細(xì)胞、293S細(xì)胞、H1648細(xì)胞

GM20270 Cells(提供STR鑒定圖譜)

HAP1 ITGA2B (-) 2 Cells(提供STR鑒定圖譜)

COLO680N Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CCC-HSF-1細(xì)胞、SNU182細(xì)胞、LS411N細(xì)胞

DMS 273 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：AN-3細(xì)胞、OCI-Ly7細(xì)胞、Hs940-T細(xì)胞

JHH-2 Cells;背景說明：肝癌；腹水轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MRC-9細(xì)胞、LP1細(xì)胞、IM95細(xì)胞

E.L.4 Cells;背景說明：EL４是從用９,１０-二甲基-１,２-并蒽在C５７BL小鼠中誘導(dǎo)的淋巴瘤中建立的。 能抗０.１ mM 化可的松，對２０ mcg/ml PHA敏感。 還有一個亞株(EL４.IL-２, ATCC TIB-１８１)可以生成高水平的IL-２。 檢測表明肢骨發(fā)育畸形病毒(鼠痘)陰性。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEL9217細(xì)胞、HEL299細(xì)胞、SVHUC細(xì)胞

STO Cells;背景說明：STO是一株繼代生長的胚成纖維細(xì)胞系，可用于制備飼養(yǎng)層細(xì)胞（feederlayers）和其他研究。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：NCIH1092細(xì)胞、WEHI3B細(xì)胞、H-146細(xì)胞

SK-N-F1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４傳代，每周換液２次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Hs 274.T細(xì)胞、IM-95細(xì)胞、SW 1271細(xì)胞

KPNRTBM1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成神經(jīng)細(xì)胞;相關(guān)產(chǎn)品有：32D clone3細(xì)胞、H 9細(xì)胞、CP-70細(xì)胞

SW 900 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H295R-S1細(xì)胞、H1563細(xì)胞、Tb1.Lu細(xì)胞

HPS1204 Cells(提供STR鑒定圖譜)

JS2 TLR4-/- D299G/T399I Cells(提供STR鑒定圖譜)

MDCC-UD13 Cells(提供STR鑒定圖譜)

ND42504 Cells(提供STR鑒定圖譜)

Psi-CRIP-MFGmIFN-gamma Cells(提供STR鑒定圖譜)

Ubigene HCT 116 HCN4 KO Cells(提供STR鑒定圖譜)

W4 [Mouse ESC] Cells(提供STR鑒定圖譜)

HCA7 colony 11 Cells(提供STR鑒定圖譜)

TE-85 clone 5 Cells;背景說明：骨肉瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TE6細(xì)胞、MRC-5細(xì)胞、FT-293細(xì)胞

UMUC-14 Cells;背景說明：腎癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCAEC細(xì)胞、NS-20Y細(xì)胞、CTLL2細(xì)胞

H1734 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：６傳代。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：H-250細(xì)胞、211H細(xì)胞、BE2C細(xì)胞

WISH Cells;背景說明：最初以為這株細(xì)胞的起源是正常羊膜，但隨后通過同工酶分析、HeLa標(biāo)記染色體和DNA指紋法分析，證實該細(xì)胞是HeLa細(xì)胞污染的；角蛋白陽性。;傳代方法：１：２-１：４傳代，每周２-３次。;生長特性：貼壁生長　;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：OLN 93細(xì)胞、OVCA433細(xì)胞、SW-1116細(xì)胞

RGCs Cells;背景說明：視網(wǎng)膜；神經(jīng)節(jié) Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK-MES-1細(xì)胞、C81-61細(xì)胞、3T6 Swiss Albino細(xì)胞

RGCs Cells;背景說明：視網(wǎng)膜；神經(jīng)節(jié) Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK-MES-1細(xì)胞、C81-61細(xì)胞、3T6 Swiss Albino細(xì)胞

PJ34 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：P3HRI細(xì)胞、SNU-878細(xì)胞、HOP 62細(xì)胞

HSC-4 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１ x １０^５ cells/１０cm dish;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：RPMC細(xì)胞、COLO 679細(xì)胞、SK-N-BE細(xì)胞

Metastatic Variant 522 Cells;背景說明：肺腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：ZR-75-30細(xì)胞、MV3細(xì)胞、MKN-74細(xì)胞

SF-126 Cells;背景說明：該細(xì)胞來源于星形膠質(zhì)細(xì)胞瘤；膠質(zhì)纖維酸性蛋白（GFAP）陰性；可以特異地結(jié)合β-內(nèi)啡肽。;傳代方法：１：３傳代；３-４天１次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：HGSMC細(xì)胞、OCIAML2細(xì)胞、Lu-99A細(xì)胞

RGC-6 Cells;背景說明：膠質(zhì)細(xì)胞株C６是由Benda等用N-nitrosomethylurea誘導(dǎo)的大鼠膠質(zhì)瘤克隆，并經(jīng)過一系列的體外培養(yǎng)和動物傳代交替后建成的。 當(dāng)細(xì)胞從低密度生長到滿瓶時，S-１００產(chǎn)量增加１０倍。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：RPMI7666細(xì)胞、RKO-AS45-1細(xì)胞、RCC10 RGB細(xì)胞

RGC5 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HeLa.S3細(xì)胞、L- cell細(xì)胞、SW839細(xì)胞

PA12 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：R-1059-D細(xì)胞、Tadarida brasiliensis 1 lung細(xì)胞、EMT-6細(xì)胞

LICR-HN6 Cells;背景說明：舌鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NK10a細(xì)胞、MD Anderson-Metastatic Breast-468細(xì)胞、T-ALL 1細(xì)胞

BALB/c 3T3 clone A31 Cells;背景說明：胚胎；成纖維；自發(fā)永生；雄性；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SVHUC細(xì)胞、SUM-159細(xì)胞、H-1573細(xì)胞

SNE 3 Cells(提供STR鑒定圖譜)

WEHI-231 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H2170細(xì)胞、CCC-HPF-1細(xì)胞、SW-900細(xì)胞

Hs 683.T Cells;背景說明：該細(xì)胞源自７６歲白人男性的左顳葉側(cè)膠質(zhì)瘤組織，有微絨毛，無橋粒。 ;傳代方法：１：４傳代，每周換液２次;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：TPC1細(xì)胞、RPTC細(xì)胞、HS5細(xì)胞

LMH Cells;背景說明：肝癌；雄性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SAOS 2細(xì)胞、Madin-Darby Canine Kidney細(xì)胞、NCI-H920細(xì)胞

Hs 870.T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：３傳代；每周換液２-３次;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：RPVSMC細(xì)胞、MRC5細(xì)胞、KYSE510細(xì)胞

U-118MG Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PK-15細(xì)胞、293EBNA細(xì)胞、HPDEC細(xì)胞

HLEC Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：50.B1細(xì)胞、HEK293A細(xì)胞、KE-39細(xì)胞

Capan-1人胰腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

U118 Cells;背景說明：注意： 據(jù)報道來自不同個體的膠質(zhì)母細(xì)胞瘤細(xì)胞株U-１１８ MG (HTB-１５) 和 U-１３８ MG (HTB-１６)有著一致的VNTR和相近的STR模式。 U-１１８ MG 和 U-１３８ MG細(xì)胞遺傳學(xué)上很相似并有至少六個衍生標(biāo)記染色體。 這是１９６６年至１９６９年間J. Ponten和同事從惡性神經(jīng)膠質(zhì)瘤中構(gòu)建的細(xì)胞株中的一株(其它包括ATCC HTB-１４和 ATCC HTB-１６ and ATCC HTB-１７)。 １９８７年用BM-Cycline培養(yǎng)６周去除了支原體污染。 ;傳代方法： 消化３-５分鐘。１：２傳代。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：混合型;相關(guān)產(chǎn)品有：HNE-2細(xì)胞、GM17346細(xì)胞、MRAEC細(xì)胞

HuH1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H747細(xì)胞、Wien133細(xì)胞、AKR細(xì)胞

HS-294T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：混合星狀和多邊形;相關(guān)產(chǎn)品有：HF-91細(xì)胞、Hep 2細(xì)胞、LIXC002細(xì)胞

HuPT4 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MC-38細(xì)胞、CEM-0細(xì)胞、Panc 04.03細(xì)胞

HOP92 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MCF.7細(xì)胞、NUGC3細(xì)胞、251 MG細(xì)胞

4175 Cells;背景說明：乳腺癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OVCAR433細(xì)胞、TE 32.T細(xì)胞、H-865細(xì)胞

Centre Antoine Lacassagne-27 Cells;背景說明：該細(xì)胞１９８２年由J. Gioanni建系，源自一位５６歲白人男性的舌頭中倍的病變部位，角蛋白強(qiáng)陽性;傳代方法：１：６傳代，２—３天換液一次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：P3-X63-Ag8細(xì)胞、SK-UT-1細(xì)胞、Human Kidney-2細(xì)胞

RPMI 6666 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：UMUC14細(xì)胞、PC-10細(xì)胞、LU65細(xì)胞

BayGenomics ES cell line RRO171 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YHB238 Cells(提供STR鑒定圖譜)

H572 Cells(提供STR鑒定圖譜)

PCC3/A/1 Cells(提供STR鑒定圖譜)

AOBA-1 Cells(提供STR鑒定圖譜)

HPL1E Cells(提供STR鑒定圖譜)

" "PubMed=7017212; DOI=10.1093/jnci/66.6.1003

Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.

HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.

J. Natl. Cancer Inst. 66:1003-1012(1981)

PubMed=7459858

Rousset M., Zweibaum A., Fogh J.

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Cancer Res. 41:1165-1170(1981)

PubMed=6278935; PMCID=PMC1916189

Kyriazis A.P., Kyriazis A.A., Scarpelli D.G., Fogh J., Rao M.S., Lepera R.

Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics.

Am. J. Pathol. 106:250-260(1982)

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=1764370; DOI=10.1038/bjc.1991.467; PMCID=PMC1977874

Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N., Lane D.P., Lemoine N.R.

Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.

Br. J. Cancer 64:1076-1082(1991)

PubMed=8426738

Kalthoff H., Schmiegel W.H., Roeder C., Kasche D., Schmidt A., Lauer G., Thiele H.-G., Honold G., Pantel K., Riethmuller G., Scherer E., Maurer J., Maacke H., Deppert W.

p53 and K-RAS alterations in pancreatic epithelial cell lesions.

Oncogene 8:289-298(1993)

PubMed=8026879; DOI=10.1002/ijc.2910580207

Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.

Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.

Int. J. Cancer 58:185-191(1994)

PubMed=8286197; DOI=10.1038/bjc.1994.24; PMCID=PMC1968784

Lohr J.-M., Trautmann B., Gottler M., Peters S., Zauner I., Maillet B., Kloppel G.

Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins.

Br. J. Cancer 69:144-151(1994)

PubMed=8968085

Goggins M.G., Schutte M., Lu J., Moskaluk C.A., Weinstein C.L., Petersen G.M., Yeo C.J., Jackson C.E., Lynch H.T., Hruban R.H., Kern S.E.

Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

Cancer Res. 56:5360-5364(1996)

PubMed=9331070

Teng D.H.-F., Perry W.L. 3rd, Hogan J.K., Baumgard M.L., Bell R., Berry S., Davis T., Frank D., Frye C., Hattier T., Hu R., Jammulapati S., Janecki T., Leavitt A., Mitchell J.T., Pero R., Sexton D., Schroeder M., Su P.-H., Swedlund B., Kyriakis J.M., Avruch J., Bartel P., Wong A.K.C., Oliphant A., Thomas A., Skolnick M.H., Tavtigian S.V.

Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.

Cancer Res. 57:4177-4182(1997)

PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4; PMCID=PMC1850008

Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A., Meltzer P.S., Ried T.

Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.

Am. J. Pathol. 154:525-536(1999)

PubMed=10408907; DOI=10.1016/S0304-3835(98)00380-2

Bartsch D.K., Barth P., Bastian D., Ramaswamy A., Gerdes B., Chaloupka B., Deiss Y., Simon B., Schudy A.

Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas.

Cancer Lett. 139:43-49(1999)

PubMed=11169957; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1014>3.0.CO;2-U

Wallrapp C., Hahnel S., Boeck W., Soder A., Mincheva A., Lichter P., Leder G., Gansauge F., Sorio C., Scarpa A., Gress T.M.

Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis.

Int. J. Cancer 91:340-344(2001)

PubMed=11668190; DOI=10.1177/002215540104901105

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

Immunocytochemical analysis of cell lines derived from solid tumors.

J. Histochem. Cytochem. 49:1369-1378(2001)

PubMed=12692724; DOI=10.1007/s00428-003-0784-4

Sipos B., Moser S., Kalthoff H., Torok V., Lohr J.-M., Kloppel G.

A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.

Virchows Arch. 442:444-452(2003)

PubMed=14695172

Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L.-C., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M.G., Hruban R.H.

Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.

Cancer Res. 63:8614-8622(2003)

PubMed=15162061; DOI=10.1159/000077512

Grigorova M., Staines J.M., Ozdag H., Caldas C., Edwards P.A.W.

Possible causes of chromosome instability: comparison of chromosomal abnormalities in cancer cell lines with mutations in BRCA1, BRCA2, CHK2 and BUB1.

Cytogenet. Genome Res. 104:333-340(2004)

PubMed=15367885; DOI=10.1097/00006676-200410000-00004

Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M., Hirohashi S.

Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.

Pancreas 29:193-203(2004)

PubMed=16912165; DOI=10.1158/0008-5472.CAN-06-0721

Calhoun E.S., Hucl T., Gallmeier E., West K.M., Arking D.E., Maitra A., Iacobuzio-Donahue C.A., Chakravarti A., Hruban R.H., Kern S.E.

Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.

Cancer Res. 66:7920-7928(2006)

PubMed=18264088; DOI=10.1038/nature06548

Edwards S.L., Brough R., Lord C.J., Natrajan R., Vatcheva R., Levine D.A., Boyd J., Reis-Filho J.S., Ashworth A.

Resistance to therapy caused by intragenic deletion in BRCA2.

Nature 451:1111-1115(2008)

PubMed=18298655; DOI=10.1111/j.1582-4934.2008.00289.x; PMCID=PMC3828895

Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A., Wellmann A., Braunschweig T., Lohr J.-M., Jesenofsky R., Friess H., Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F., Schackert H.K., Kloppel G., Kalthoff H., Saeger H.-D., Grutzmann R.

Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling.

J. Cell. Mol. Med. 12:2823-2835(2008)

PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x; PMCID=PMC11158928

Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A., Shiratori K., Hirohashi S., Inazawa J., Imoto I.

Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.

Cancer Sci. 99:986-994(2008)

CLPUB00416

Oberlin L.

Treatment of pancreatic carcinoma cell lines in vitro and vivo with a monoclonal antibody against the transferrin receptor.

Thesis VMD (2009); Justus-Liebig-Universitat Giessen; Giessen; Germany

DOI=10.4172/jpb.1000057

Yamada M., Fujii K., Koyama K., Hirohashi S., Kondo T.

The proteomic profile of pancreatic cancer cell lines corresponding to carcinogenesis and metastasis.

J. Proteomics Bioinformatics 2:1-18(2009)

PubMed=20037478; DOI=10.4161/cbt.8.21.9685; PMCID=PMC2824894

Kent O.A., Mullendore M.E., Wentzel E.A., Lopez-Romero P., Tan A.-C., Alvarez H., West K.M., Ochs M.F., Hidalgo M., Arking D.E., Maitra A., Mendell J.T.

A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.

Cancer Biol. Ther. 8:2013-2024(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963; PMCID=PMC2860631

Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J.G., Scaife C.L., Firpo M.A., Mulvihill S.J.

Phenotype and genotype of pancreatic cancer cell lines.

Pancreas 39:425-435(2010)

PubMed=21750719; DOI=10.1371/journal.pone.0021639; PMCID=PMC3130048

Barber L.J., Rosa Rosa J.M., Kozarewa I., Fenwick K., Assiotis I., Mitsopoulos C., Sims D., Hakas J., Zvelebil M., Lord C.J., Ashworth A.

Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer.

PLoS ONE 6:E21639-E21639(2011)

PubMed=22109279; DOI=10.1007/s13577-011-0037-9

Ding Q., Yoshimitsu M., Kuwahata T., Maeda K., Hayashi T., Obara T., Miyazaki Y., Matsubara S., Natsugoe S., Takao S.

Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial-mesenchymal transition in pancreatic cancer.

Hum. Cell 25:1-8(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

DOI=10.4172/2324-9293.1000104

Wagenhauser M.U., Ruckert F., Niedergethmann M., Grutzmann R., Saeger H.-D.

Distribution of characteristic mutations in native ductal adenocarcinoma of the pancreas and pancreatic cancer cell lines.

Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013)

PubMed=25167228; DOI=10.1038/bjc.2014.475; PMCID=PMC4453732

Hamidi H., Lu M., Chau K., Anderson L., Fejzo M.S., Ginther C., Linnartz R., Zubel A., Slamon D.J., Finn R.S.

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Br. J. Cancer 111:1788-1801(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27259358; DOI=10.1074/mcp.M116.058313; PMCID=PMC4974343

Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M., Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K., Biankin A.V., Wu J.-M., Daly R.J.

Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.

Mol. Cell. Proteomics 15:2671-2685(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051; PMCID=PMC6343826

Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.

Differential effector engagement by oncogenic KRAS.

Cell Rep. 22:1889-1902(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9

Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Nature 568:511-516(2019)"